Compare Ascendis Pharma A/S (ASND) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Gigacloud Technology Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Gigacloud Technology Inc trades at $34.28 (market cap $1.25B). The key difference: Ascendis Pharma A/S is far larger — about 14.2× Gigacloud Technology Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GCT | |
|---|---|---|
Market Cap | $17.74B | $1.25B |
Sector | Health | Technology |
52-Week High | $277.18 | $51.80 |
52-Week Low | $163.32 | $20.26 |
Enterprise Value | $18.11B | $1.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GigaCloud Technology (GCT) trades at $34.41, down 1.21% today, with a bullish technical signal and strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate, and maintains robust profitability with a 10.77% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.4B in 2026, supported by positive analyst sentiment and inclusion in TIME's World's Growth Leaders 2026 list.
The outlook for GCT is positive, driven by earnings momentum and strategic expansions into Europe and AI-edge technology. Key risks include market volatility, competitive pressures in the furniture sector, and potential fiduciary concerns highlighted in recent news. With 66.7% of analysts rating it a Buy and a $56 price target from Seeking Alpha suggesting 76% upside, the stock presents growth potential but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
